心血管疾病和风险因素中的非编码RNA疗法:系统审查
Meity Ardiana1,2, Asiyah Nurul Fadila1,2, Zakirah Zuhra1,2
1Department of Cardiology and Vascular Medicine, Dr.Soetomo General Hospital, Surabaya, Indonesia.
Non-coding RNA research
|July 24, 2023
概括
基于RNA的疗法,包括aptamer和反感性寡核酸 (ASO),显示出治疗心血管疾病 (CVD) 的前景. 虽然在早期试验中通常是安全和有效的,但需要进一步的研究才能充分确定它们的治疗潜力.
科学领域:
- 生物医学科学 生物医学科学
- 分子生物学分子生物学
- 心血管医学 心血管医学
背景情况:
- 基于RNA的疗法正在成为治疗心血管疾病 (CVD) 的重要兴趣领域.
- 目前的方法包括非编码RNAs (ncRNAs),反意义寡核酸 (ASOs) 和aptamers,针对涉及心血管疾病的特定基因.
- 尽管人们越来越关注,但支持这些基于RNA的干预措施的临床数据仍处于初步阶段.
研究的目的:
- 系统地审查基于RNA的治疗心血管疾病 (CVD) 和相关风险因素的有效性和安全性.
- 确定这些治疗策略中使用的主要类型的RNA分子.
- 评估基于RNA的心血管疾病治疗临床证据的当前阶段.
主要方法:
- 通过使用PRISMA指南进行了系统的文献审查.
- 搜索的数据库包括PubMed,Cochrane,Scopus和DOAJR. 这些数据库的搜索内容包括:
- 从最初的64篇文章中,包括了39个人类临床试验,重点是体,ASO和小干扰RNA (siRNA).
主要成果:
- 基于RNA的疗法,包括aptamers,ASOs和siRNA,在治疗各种心血管疾病方面表现出有效性.
- 这些疗法也有效地控制了心血管风险因素.
- 审查的研究表明,基于RNA的治疗方法通常是安全的,并且被患者耐受得很好.
结论:
- 基于RNA的疗法是心血管疾病管理的一个有希望的途径.
- 目前的临床证据,虽然处于早期阶段,但支持在心血管疾病治疗中使用阿普坦,ASO和siRNA的疗效和安全性.
- 需要进一步进行广泛的研究和临床调查,才能充分实现基于RNA的心脏病治疗策略的治疗潜力.
相关概念视频
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
01:30Coronary Artery Disease I: Introduction
23
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
23
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
567
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
567
01:26Coronary Artery Disease IV: Preventive Measures
25
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
25
01:27Coronary Artery Disease V: Interprofessional Care
10
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
10
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465